BCL2 and B-cell chronic lymphocytic leukemia: CLL is a kind of disease, which is commonly regarded as micro-RNA mediated over-expression of Bcl-2 protein caused by deletion of BCL-2 gene expression suppression.[32,33] Recently, a highly potent and selective oral Bcl-2 antagonist, venetoclax, has gotten the green light in CLL patients.